NHS shifts cervical‑screening triage: HPV testing to be primary filter, reducing review of HPV‑negative Pap tests

Cervical screening in England is now very clearly an HPV-first system. That sounds technical, but the real-world change is simple: the lab looks first for high-risk HPV, and if that test is negative, the person usually goes straight back to routine recall. No routine microscope review of the cells. NHS England locked that into updated pathway and laboratory guidance in July 2025, after announcing in June 2025 that HPV-negative people aged 25 to 49 would move to 5-year recall from July 1. (gov.uk) ### What actually changed in England? The big change is not that HPV became important — that happened earlier. England has tested all cervical screening samples with high-risk HPV as the primary screen since December 2019. The newer step is that the pathway is now built around the negative predictive power of that HPV result. The official care pathway says an hrHPV-negative result means return to routine recall, while cytology is used as triage only when hrHPV is detected. (england.nhs.uk) ### Does that mean HPV-negative samples skip cytology? Basically, yes in the routine pathway. The government training material says HPV primary screening means HPV is the first test and cytology is performed only when HPV is present. The lab guidance goes a step further and notes a new section on “automatic authorisation of primary HPV negative test results,” which tells you these negatives are meant to move through the system quickly and at scale. (gov.uk) ### Why is the NHS comfortable doing that? Because HPV-first screening is better at ruling out meaningful near-term risk than old-style cytology-first screening. The BMJ study behind the interval extension used English pilot data from 1.34 million women. After a negative HPV screen, women under 50 had much lower second-round CIN3+ detection than after negative cytology — (gov.uk)nusually reassuring. (bmj.com) ### So why are people worried? Because “very safe overall” is not the same as “impossible to miss.” A small minority of cervical cancers and precancers can be HPV-negative on testing, whether because of true biology, sampling issues, test limitations, or rare tumour types. In an HPV-first workflow, those cases do not automatically get the backup look at cell morphology that older cytology-led systems provided more routinely. That is the core anxiety(bmj.com) cases, not that the whole programme stopped working. (gov.uk) ### Does the NHS guidance mention discordant abnormal cytology? Not in the way critics mean, because the routine pathway barely creates that category. If cytology is generally only done after an HPV-positive result, then an “HPV-negative but high-grade cytology” rou(gov.uk)to avoid spending cytology effort on HPV-negative samples in the first place. (gov.uk) ### Is this tied to the 5-year interval story? Yes — directly. NHS England’s June 10, 2025 announcement said younger women with a negative HPV result would move from 3-year to 5-year recall from July 2025, and the July 1 protocol spells out that this applies to routine hrHPV-negative tests in people aged 24.5 to 49. The whole argument for longer intervals depends on trusting HPV negativity as the main filter. (england.nhs.uk) ### What is the bottom line? England did not quietly abandon cervical screening. It doubled down on HPV-first screening because the data say a negative HPV result predicts very low risk for most people. But the tradeoff is real — when you stop routinely reviewing HPV-negative samples under the microscope, you also reduce your chances of spotting the rare discordant case that cytology might have flagged. (gov.uk)